Atorvastatin Calcium Tablets Recalled for Manufacturing Quality Violations
Northwind Pharmaceuticals is recalling 99 bottles of Atorvastatin Calcium 10 mg tablets nationally due to manufacturing process deviations identified in March 2023.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall for manufacturing process deviations without reported illnesses or injuries. CGMP violations in the absence of confirmed harm represent precautionary recalls, which the rubric identifies as Moderate (score 2).
Plain-English summary
Northwind Pharmaceuticals LLC is voluntarily recalling Atorvastatin Calcium Tablets, USP 10 mg in 30-count bottles due to Current Good Manufacturing Practice (CGMP) deviations. The affected product is identified as NDC 51655-946-52, Lot # F117192201, with an expiration date of April 30, 2023. A total of 99 bottles were distributed nationwide across the United States.
The company initiated the recall on March 16, 2023. The FDA classified the recall as Class II. Northwind notified customers through email, fax, letter, press release, telephone, and in-person visits.
Consumers who have this medication should contact their pharmacist or healthcare provider about the recall. Patients should not stop taking atorvastatin without consulting their doctor, as the medication is essential for managing cholesterol levels. A healthcare provider can verify whether a patient's supply is affected and determine appropriate next steps.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Manufacturer
- Northwind Pharmaceuticals LLC
- Category
- Drug
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # F117192201
- Exp. Date 4/30/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin Calcium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin Calcium tablets recalled nationwide for failed dissolution specifications
FDA (Drugs) · 2025-10-22
- HighAtorvastatin Calcium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin Calcium Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27